scholarly journals Integrative proteome analysis implicates aberrant RNA splicing in impaired developmental potential of aged mouse oocytes

Aging Cell ◽  
2021 ◽  
Author(s):  
Mingrui Li ◽  
Chao Ren ◽  
Shuai Zhou ◽  
Yuanlin He ◽  
Yueshuai Guo ◽  
...  
2013 ◽  
Vol 20 (5) ◽  
pp. 1135-1145 ◽  
Author(s):  
Sophia Adamia ◽  
Benjamin Haibe-Kains ◽  
Patrick M. Pilarski ◽  
Michal Bar-Natan ◽  
Samuel Pevzner ◽  
...  

1995 ◽  
Vol 10 (7) ◽  
pp. 1810-1815 ◽  
Author(s):  
Ricardo T. Serta ◽  
Jiannis Michalopoulos ◽  
Machelle M. Seibel ◽  
Ann A. Kiessling

Blood ◽  
1998 ◽  
Vol 91 (6) ◽  
pp. 2152-2156 ◽  
Author(s):  
Jada Lewis ◽  
Baoli Yang ◽  
Ronald Kim ◽  
Halina Sierakowska ◽  
Ryszard Kole ◽  
...  

Abstract The βIVS-2-654 C→T mutation accounts for approximately 20% of β thalassemia mutations in southern China; it causes aberrant RNA splicing and leads to β0 thalassemia. To provide an animal model for testing therapies for correcting splicing defects, we have used the “plug and socket” method of gene targeting in murine embryonic stem cells to replace the two (cis) murine adult β globin genes with a single copy of the human βIVS-2-654 gene. No homozygous mice survive postnatally. Heterozygous mice carrying this mutant gene produce reduced amounts of the mouse β globin chains and no human β globin, and have a moderate form of β thalassemia. The heterozygotes show the same aberrant splicing as their human counterparts and provide an animal model for testing therapies to correct splicing defects at either the RNA or DNA level.


2019 ◽  
Vol 112 (3) ◽  
pp. e251
Author(s):  
Isao Takehara ◽  
Hideki Igarashi ◽  
Kyoko Takahashi ◽  
Michi Nishi ◽  
Koki Matsuo ◽  
...  

Biomolecules ◽  
2020 ◽  
Vol 10 (5) ◽  
pp. 680 ◽  
Author(s):  
Asmaa Samy ◽  
Baris Suzek ◽  
Mehmet Ozdemir ◽  
Ozge Sensoy

Cancer is the second leading cause of death worldwide. The etiology of the disease has remained elusive, but mutations causing aberrant RNA splicing have been considered one of the significant factors in various cancer types. The association of aberrant RNA splicing with drug/therapy resistance further increases the importance of these mutations. In this work, the impact of the splicing factor 3B subunit 1 (SF3B1) K700E mutation, a highly prevalent mutation in various cancer types, is investigated through molecular dynamics simulations. Based on our results, K700E mutation increases flexibility of the mutant SF3B1. Consequently, this mutation leads to i) disruption of interaction of pre-mRNA with SF3B1 and p14, thus preventing proper alignment of mRNA and causing usage of abnormal 3’ splice site, and ii) disruption of communication in critical regions participating in interactions with other proteins in pre-mRNA splicing machinery. We anticipate that this study enhances our understanding of the mechanism of functional abnormalities associated with splicing machinery, thereby, increasing possibility for designing effective therapies to combat cancer at an earlier stage.


2017 ◽  
Author(s):  
Anant A. Agrawal ◽  
Michael Seiler ◽  
Lindsey Brinton ◽  
Rose Mantel ◽  
Rosa Lapalombella ◽  
...  

2019 ◽  
Vol 3 (1) ◽  
pp. 167-185 ◽  
Author(s):  
Luisa Escobar-Hoyos ◽  
Katherine Knorr ◽  
Omar Abdel-Wahab

RNA splicing, the enzymatic process of removing segments of premature RNA to produce mature RNA, is a key mediator of proteome diversity and regulator of gene expression. Increased systematic sequencing of the genome and transcriptome of cancers has identified a variety of means by which RNA splicing is altered in cancer relative to normal cells. These findings, in combination with the discovery of recurrent change-of-function mutations in splicing factors in a variety of cancers, suggest that alterations in splicing are drivers of tumorigenesis. Greater characterization of altered splicing in cancer parallels increasing efforts to pharmacologically perturb splicing and early-phase clinical development of small molecules that disrupt splicing in patients with cancer. Here we review recent studies of global changes in splicing in cancer, splicing regulation of mitogenic pathways critical in cancer transformation, and efforts to therapeutically target splicing in cancer.


Author(s):  
Gou Yamamoto ◽  
Izumi Miyabe ◽  
Keisuke Tanaka ◽  
Miho Kakuta ◽  
Motoko Watanabe ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document